The International Prognostic Index was developed prior to the development of rituximab. The revised IPI is a rescaling based on current outcomes.
Parameters:
(1) age of the patient in years
(2) serum LDH in U/L relative to the upper limit of the normal reference range (ULN)
(3) ECOG performance status
(4) Ann Arbor stage
(5) extranodal sites
Parameter |
Finding |
Points |
age of the patient |
<= 60 years |
0 |
|
> 60 years |
1 |
serum LDH |
<= ULN |
0 |
|
> ULN |
1 |
ECOG performance |
0 or 1 |
0 |
|
2 to 4 |
1 |
Ann Arbor stage |
I or II |
0 |
|
III or IV |
1 |
extranodal sites |
<= 1 |
0 |
|
>= 2 |
1 |
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
Revised IPI Score |
Risk Group |
4 Year Overall Survival |
0 |
very good |
94% |
1 or 2 |
good |
79% |
3 to 5 |
poor |
55% |
Original IPI Score |
Risk Group |
4 Year Overall Survival |
0 or 1 |
low |
82% |
2 |
low-intermediate |
81% |
3 |
high-intermediate |
49% |
4 or 5 |
high |
59% |
Purpose: To evaluate a patient with diffuse large B-cell lymphoma (DLBCL) using the Revised International Prognostic Index (R-IPI)
Specialty: Hematology Oncology
Objective: severity, prognosis, stage
ICD-10: C83.3,